Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis - Sagimet Biosciences (NASDAQ:SGMT)
Denifanstat met all primary and secondary endpoints versus placebo Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, TVB-3567, for development in acne SAN MATEO, Calif., Sept. 17, 2025 ( GLOBE NEWSWIRE ) -- Sagimet Biosciences Inc.
How this was made

The 30-second read
Why it matters
The successful trial outcomes are likely to boost investor confidence, potentially leading to stock price appreciation and increased interest from biotech investors.
Market read
The news is highly relevant for investors and traders focusing on biotech and pharmaceutical sectors, especially those with exposure to Sagimet Biosciences.
What to watch
Potential regulatory hurdles, market competition, and the company's overall financial health could influence stock performance despite positive trial results.
Background
Sagimet Biosciences has announced positive Phase 3 results for Denifanstat, a drug candidate for moderate to severe acne, marking a significant milestone in its clinical development.
Ticker impact
The news pertains directly to Sagimet Biosciences Inc. (NASDAQ: SGMT), indicating potential positive impact due to successful clinical trial results.
Moderate to significant upward movement in SGMT stock price within the short to medium term.
The successful trial outcomes meet key development milestones, likely leading to increased market interest and valuation adjustments.
Market effects
Potential positive impact on biotech and life sciences sectors, especially companies involved in dermatology and acne treatments.
Primarily US-focused due to NASDAQ listing, with potential global interest as clinical results gain recognition.
Moderate, as the news pertains to a specific drug development milestone with potential global market implications.
Counterpoint
Some skepticism may exist regarding the translation of clinical trial success into commercial success, which could limit stock appreciation.
Key entities
- CompanySagimet Biosciences Inc.
Biotech firm developing novel therapies for dermatological conditions.
- Drug CandidateDenifanstat
A drug developed by Sagimet for the treatment of moderate to severe acne.





